Novartis/GSK Cancer Deal Gets FTC OK Based On Existing Divestments
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ transfer of Phase III BRAF and MEK inhibitors to partner Array BioPharma satisfies Federal Trade Commission’s anticompetitive concerns; no divestiture yet announced for GSK acquisition of Novartis [See Deal]vaccines.